Intramuscular Anti-D treatment for immune thrombocytopenia: A single centre experience

Intravenous Anti-Rhesus-D immunoglobulin (Anti-D) is a first-line treatment option for immune thrombocytopenia in non-splenectomised and RhD-positive patients. In this report, we retrospectively review our experience with intramuscular (IM) Anti-D treatment in 74 adult patients between 1990 and 2018. We found that 73% of patients showed a response; almost all of them had complete responses (68.89%), and 26% achieved complete responses sustained at least 6 months after treatment discontinuation. No significant side effects were observed with no cases of acute haemolysis or anaemia reported. We conclude from this study that IM Anti-D is an effective and safe treatment for immune thrombocytopenia.

Automated summary

The report retrospectively reviews the use of IM Anti-D treatment in 74 adult patients, and concludes that it is an effective and safe treatment option for immune thrombocytopenia.